These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20608936)

  • 1. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
    Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
    Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
    Miyoshi S; Hamada H; Hamaguchi N; Kato A; Katayama H; Irifune K; Ito R; Miyazaki T; Okura T; Higaki J
    Int J Oncol; 2012 Aug; 41(2):449-56. PubMed ID: 22580933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
    Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
    J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer.
    Fujita M; Hasegawa A; Yamamori M; Okamura N
    J Exp Clin Cancer Res; 2017 Jul; 36(1):91. PubMed ID: 28673319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
    Van TT; Hanibuchi M; Kakiuchi S; Sato S; Kuramoto T; Goto H; Mitsuhashi A; Nishioka Y; Akiyama S; Sone S
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):497-504. PubMed ID: 21079960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells.
    Vitale G; Zappavigna S; Marra M; Dicitore A; Meschini S; Condello M; Arancia G; Castiglioni S; Maroni P; Bendinelli P; Piccoletti R; van Koetsveld PM; Cavagnini F; Budillon A; Abbruzzese A; Hofland LJ; Caraglia M
    Biotechnol Adv; 2012; 30(1):169-84. PubMed ID: 21871555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells.
    Yan KH; Yao CJ; Chang HY; Lai GM; Cheng AL; Chuang SE
    Mol Carcinog; 2010 Mar; 49(3):235-46. PubMed ID: 19908241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
    Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
    Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.
    Stewart JH; Tran TL; Levi N; Tsai WS; Schrump DS; Nguyen DM
    J Surg Res; 2007 Jul; 141(1):120-31. PubMed ID: 17574045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.
    Nakataki E; Yano S; Matsumori Y; Goto H; Kakiuchi S; Muguruma H; Bando Y; Uehara H; Hamada H; Kito K; Yokoyama A; Sone S
    Cancer Sci; 2006 Mar; 97(3):183-91. PubMed ID: 16542214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth.
    Li M; Lee TW; Mok TS; Warner TD; Yim AP; Chen GG
    J Cell Biochem; 2005 Nov; 96(4):760-74. PubMed ID: 16149072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
    Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
    Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
    Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
    Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
    [No Abstract]   [Full Text] [Related]  

  • 16. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
    Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
    Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity.
    Baek SJ; Wilson LC; Hsi LC; Eling TE
    J Biol Chem; 2003 Feb; 278(8):5845-53. PubMed ID: 12475986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troglitazone attenuates epidermal growth factor receptor signaling independently of peroxisome proliferator-activated receptor in PC-3 cells.
    Zhu H; Pan X; Qi H; Wang X; Hou S; Han B; Liu Z; Xu L
    Oncol Rep; 2011 Jan; 25(1):81-90. PubMed ID: 21109961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
    Edakuni N; Ikuta K; Yano S; Nakataki E; Muguruma H; Uehara H; Tani M; Yokota J; Aizawa H; Sone S
    Oncol Res; 2006; 16(5):235-43. PubMed ID: 17294804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
    Zanellato I; Colangelo D; Osella D
    Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.